Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients

BACKGROUND: Compared to the general population, cancer patients are at higher risk of morbidity and mortality following SARS‐CoV‐2 infection. The immune response to a two‐dose regimen of mRNA vaccines in cancer patients is generally lower than in immunocompetent individuals. Booster doses may meanin...

Descripción completa

Detalles Bibliográficos
Autores principales: Giuliano, Anna, Kuter, Barbara, Pilon‐Thomas, Shari, Whiting, Junmin, Mo, Qianxing, Leav, Brett, Sirak, Bradley, Cubitt, Christopher, Dukes, Christopher, Isaacs‐Soriano, Kimberly, Kennedy, Kayoko, Ball, Somedeb, Dong, Ning, Jain, Akriti, Hwu, Patrick, Lancet, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354405/
https://www.ncbi.nlm.nih.gov/pubmed/37377402
http://dx.doi.org/10.1002/cac2.12453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354405/
https://www.ncbi.nlm.nih.gov/pubmed/37377402
http://dx.doi.org/10.1002/cac2.12453

Ejemplares similares